www.medrxiv.org
Open in
urlscan Pro
104.18.17.209
Public Scan
URL:
https://www.medrxiv.org/content/10.1101/2021.06.25.21259544v1
Submission: On October 18 via api from QA — Scanned from DE
Submission: On October 18 via api from QA — Scanned from DE
Form analysis 2 forms found in the DOM
POST /content/10.1101/2021.06.25.21259544v1
<form class="highwire-quicksearch button-style-mini button-style-mini" action="/content/10.1101/2021.06.25.21259544v1" method="post" id="highwire-search-quicksearch-form-0" accept-charset="UTF-8">
<div>
<div class="form-item form-item-label-invisible form-type-textfield form-item-keywords">
<label class="element-invisible" for="edit-keywords">Search for this keyword </label>
<input placeholder="Search" type="text" id="edit-keywords" name="keywords" value="" size="60" maxlength="128" class="form-text">
</div>
<div class="button-wrapper button-mini"><span class="icon-search"></span><input data-icon-only="1" data-font-icon="icon-search" data-icon-position="after" type="submit" id="edit-submit--2" name="op" value="Search" class="form-submit"></div><input
type="hidden" name="form_build_id" value="form-QVGJvfZuQ_4SpeTeEZB8boJkXv_u4dZ331HKgRHNrT4">
<input type="hidden" name="form_id" value="highwire_search_quicksearch_form_0">
</div>
</form>POST /content/10.1101/2021.06.25.21259544v1
<form action="/content/10.1101/2021.06.25.21259544v1" method="post" id="forward-form" accept-charset="UTF-8">
<div>
<div id="edit-instructions" class="form-item form-item-label-before form-type-item">
<p>Thank you for your interest in spreading the word about medRxiv.</p>
<p>NOTE: Your email address is requested solely to identify you as the sender of this article.</p>
</div>
<div class="form-item form-item-label-before form-type-textfield form-item-email">
<label for="edit-email">Your Email <span class="form-required" title="This field is required.">*</span></label>
<input type="text" id="edit-email" name="email" value="" size="58" maxlength="256" class="form-text required">
</div>
<div class="form-item form-item-label-before form-type-textfield form-item-name">
<label for="edit-name">Your Name <span class="form-required" title="This field is required.">*</span></label>
<input type="text" id="edit-name" name="name" value="" size="58" maxlength="256" class="form-text required">
</div>
<div class="form-item form-item-label-before form-type-textarea form-item-recipients">
<label for="edit-recipients">Send To <span class="form-required" title="This field is required.">*</span></label>
<div class="form-textarea-wrapper resizable textarea-processed resizable-textarea"><textarea id="edit-recipients" name="recipients" cols="50" rows="5" class="form-textarea required"></textarea>
<div class="grippie"></div>
</div>
<div class="description">Enter multiple addresses on separate lines or separate them with commas.</div>
</div>
<div id="edit-page" class="form-item form-item-label-before form-type-item">
<label for="edit-page">You are going to email the following </label>
<a href="/content/10.1101/2021.06.25.21259544v1" class="active" data-icon-position="" data-hide-link-title="0">Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers</a>
</div>
<div id="edit-subject" class="form-item form-item-label-before form-type-item">
<label for="edit-subject">Message Subject </label> (Your Name) has forwarded a page to you from medRxiv
</div>
<div id="edit-body" class="form-item form-item-label-before form-type-item">
<label for="edit-body">Message Body </label> (Your Name) thought you would like to see this page from the medRxiv website.
</div>
<div class="form-item form-item-label-before form-type-textarea form-item-message">
<label for="edit-message--2">Your Personal Message </label>
<div class="form-textarea-wrapper resizable textarea-processed resizable-textarea"><textarea id="edit-message--2" name="message" cols="50" rows="10" class="form-textarea"></textarea>
<div class="grippie"></div>
</div>
</div>
<input type="hidden" name="path" value="node/373228">
<input type="hidden" name="path_cid" value="">
<input type="hidden" name="forward_footer" value=" ">
<input type="hidden" name="form_build_id" value="form--cr8FmKLlPKTX0WvhUHy3AjZQHv3wCjwM8MBMAJi73g">
<input type="hidden" name="form_id" value="forward_form">
<fieldset class="captcha form-wrapper">
<legend><span class="fieldset-legend">CAPTCHA</span></legend>
<div class="fieldset-wrapper">
<div class="fieldset-description">This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.</div><input type="hidden" name="captcha_sid" value="154584682">
<input type="hidden" name="captcha_token" value="2fc9af1fb009bf922c1ceb244107d4b0">
<input type="hidden" name="captcha_response" value="Google no captcha">
<div class="g-recaptcha recaptcha-processed" data-sitekey="6LfnJVIUAAAAAE-bUOMg0MJGki4lqSvDmhJp19fN" data-theme="light" data-type="image">
<div style="width: 304px; height: 78px;">
<div><iframe title="reCAPTCHA"
src="https://www.google.com/recaptcha/api2/anchor?ar=1&k=6LfnJVIUAAAAAE-bUOMg0MJGki4lqSvDmhJp19fN&co=aHR0cHM6Ly93d3cubWVkcnhpdi5vcmc6NDQz&hl=en&type=image&v=qljbK_DTcvY1PzbR7IG69z1r&theme=light&size=normal&cb=tzp6mtmqp6eo"
width="304" height="78" role="presentation" name="a-abkup5k6m4rf" frameborder="0" scrolling="no"
sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox"></iframe></div><textarea id="g-recaptcha-response" name="g-recaptcha-response"
class="g-recaptcha-response" style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea>
</div><iframe style="display: none;"></iframe>
</div>
</div>
</fieldset>
<div class="form-actions form-wrapper" id="edit-actions"><input type="submit" id="edit-submit" name="op" value="Send Message" class="form-submit"></div>
</div>
</form>Text Content
Skip to main content * Home * About * Submit * News & Notes * ALERTS / RSS Search for this keyword Advanced Search Comment on this paper ADVERSE EFFECTS AND ANTIBODY TITERS IN RESPONSE TO THE BNT162B2 MRNA COVID-19 VACCINE IN A PROSPECTIVE STUDY OF HEALTHCARE WORKERS Si’Ana A. Coggins, Eric D. Laing, Cara H. Olsen, Emilie Goguet, Matthew Moser, Belinda M. Jackson-Thompson, Emily C. Samuels, Simon D. Pollett, David R. Tribble, Julian Davies, Luca Illinik, Monique Hollis-Perry, Santina E. Maiolatesi, Christopher A. Duplessis, Kathleen F. Ramsey, Anatalio E. Reyes, Yolanda Alcorta, Mimi A. Wong, Gregory Wang, Orlando Ortega, Edward Parmelee, Alyssa R. Lindrose, Andrew L. Snow, Allison M.W. Malloy, Andrew G. Letizia, John H. Powers III, Timothy H. Burgess, Christopher C. Broder, Edward Mitre doi: https://doi.org/10.1101/2021.06.25.21259544 This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. Si’Ana A. Coggins 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Eric D. Laing 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Cara H. Olsen 3Department of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Emilie Goguet 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Matthew Moser 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Belinda M. Jackson-Thompson 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Emily C. Samuels 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Simon D. Pollett 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA 4Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site David R. Tribble 4Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Julian Davies 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA 4Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Luca Illinik 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA 4Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Monique Hollis-Perry 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Santina E. Maiolatesi 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Christopher A. Duplessis 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Kathleen F. Ramsey 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA 6General Dynamics Information Technology, Falls Church, VA, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Anatalio E. Reyes 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA 6General Dynamics Information Technology, Falls Church, VA, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Yolanda Alcorta 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA 6General Dynamics Information Technology, Falls Church, VA, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Mimi A. Wong 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA 6General Dynamics Information Technology, Falls Church, VA, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Gregory Wang 5Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA 6General Dynamics Information Technology, Falls Church, VA, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Orlando Ortega 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA 4Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Edward Parmelee 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA 4Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site * For correspondence: edward.mitre@usuhs.edu Alyssa R. Lindrose 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 2Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Andrew L. Snow 7Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Allison M.W. Malloy 8Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Andrew G. Letizia 9Infectious Disease Directorate, Naval Medical Research Center, Silver Spring, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site John H. Powers III 10Clinical Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Timothy H. Burgess 4Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Christopher C. Broder 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site Edward Mitre 1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA * Find this author on Google Scholar * Find this author on PubMed * Search for this author on this site * Abstract * Full Text * Info/History * Metrics * Supplementary material * Data/Code * Preview PDF ABSTRACT Background mRNA COVID-19 vaccines are playing a key role in controlling the COVID-19 pandemic. The relationship between post-vaccination symptoms and strength of antibody responses is unclear. Objective To determine whether adverse effects caused by vaccination with the Pfizer/BioNTech BNT162b2 vaccine are associated with the magnitude of vaccine-induced antibody levels. Design Single center, prospective, observational cohort study. Setting Participants worked at Walter Reed National Military Medical Center and were seen monthly at the Naval Medical Research Center Clinical Trials Center. Participants Generally healthy adults that were not severely immunocompromised, had no history of COVID-19, and were seronegative for SARS-CoV-2 spike protein prior to vaccination. Measures Severity of vaccine-associated symptoms was obtained through participant completed questionnaires. Testing for IgG antibodies against SARS-CoV-2 spike protein and receptor binding domain was conducted using microsphere-based multiplex immunoassays. Results 206 participants were evaluated (69.4% female, median age 41.5 years old). We found no correlation between vaccine-associated symptom severity scores and vaccine-induced antibody titers one month after vaccination. We also observed that 1) post-vaccination symptoms were inversely correlated with age and weight and more common in women, 2) systemic symptoms were more frequent after the second vaccination, 3) high symptom scores after first vaccination were predictive of high symptom scores after second vaccination, and 4) older age was associated with lower titers. Limitations Study only observes antibody responses and consists of healthy participants. Conclusions Lack of post-vaccination symptoms following receipt of the BNT162b2 vaccine does not equate to lack of vaccine-induced antibodies one month after vaccination. This study also suggests that it may be possible to design future mRNA vaccines that confer robust antibody responses with lower frequencies of vaccine-associated symptoms. Funding This study was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USUHS) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). This project has been funded by the Defense Health Program, U.S. DoD, under award HU00012120067. Project funding for JHP was in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The funding bodies have had no role in the study design or the decision to submit the manuscript for publication. COMPETING INTEREST STATEMENT The authors have declared no competing interest. FUNDING STATEMENT This study was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USUHS) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). This project has been funded by the Defense Health Program, U.S. DoD, under award HU00012120067. Project funding for JHP was in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The funding bodies have had no role in the study design or the decision to submit the manuscript for publication. AUTHOR DECLARATIONS I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study protocol was approved by the Uniformed Services University of the Health Sciences Institutional Review Board (FWA 00001628; DoD Assurance P60001) in compliance with all applicable Federal regulations governing the protection of human participants. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes FOOTNOTES * Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Naval Medical Research Center, the Department of Navy, the Department of Defense, the Henry. M. Jackson Foundation for the Advancement of Military Medicine, or the U.S. Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. * Competing Interests: The authors declare that they have no competing interests. EM, EDL, CCB, AS, AMWM, KMH-P, AGL, CAD, and THB are military Service members or employees of the U.S. Government. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military Service member or employee of the U.S. Government as part of that person’s official duties. * Ethics approval and consent to participate: This study protocol was approved by the Uniformed Services University of the Health Sciences Institutional Review Board (FWA 00001628; DoD Assurance P60001) in compliance with all applicable Federal regulations governing the protection of human participants. * All participants provided written informed consent for participation. DATA AVAILABILITY Data are available from the first (S.C.) and corresponding (E.M.) authors upon request. Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Preprint discussion sites covering this article: Rapid Reviews COVID-19, 04 Aug 2021 Review by Ming, Y; Modenese, A; Rapid Reviews COVID-19, 04 Aug 2021 Review by Ming, Y; Rapid Reviews COVID-19, 04 Aug 2021 Review by Modenese, A; Blog posts linking to this article: Devdiscourse, 02 Jul 2021 The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and… Tweets referencing this article: 815 followers Hanna Metsola @HannaMetsola RT @MikaelNiku: @HannaMetsola @LeenaViikari Kaivelin sittenkin vähän, koska tämähän kiinnostaa kaikkia! Tässä yksi pienehkö tutkimus (prepr… 14 Sep 2021 ReplyRetweetFavourite 3,016 followers Mikael Niku @MikaelNiku @HannaMetsola @LeenaViikari Kaivelin sittenkin vähän, koska tämähän kiinnostaa kaikkia! Tässä yksi pienehkö tutkimus (preprint), joka tuli vastaan. Tässä ei havaittu yhteyttä rokotereaktion ja vasta-ainetasojen välillä. En hirmu syvällisesti syynännyt tote 14 Sep 2021 ReplyRetweetFavourite 903 followers 高性能ウ○コ製造機の㋐ライさん💩🧀💉💉 @odaraisan1 相関は無さそうだし、解熱剤は使えば良さそうなのだ。 https://t.co/lPlaG7UlPl https://t.co/p2pDnG33Pa 08 Sep 2021 ReplyRetweetFavourite 25 followers twitXiv @twitXiv RT @Cycle4: This is a pre-print, but for anyone worried because they did not have symptoms after vaccine- here’s more evidence that reactio… 26 Aug 2021 ReplyRetweetFavourite 513 followers ﾀﾞﾗｲﾄﾞｼﾞｪｼﾞｪﾛ @jejerep122 @raveve1416 https://t.co/QJh8pXosbh 査読前論文ですが、上記調査データでは、性別・年齢差による副反応の強さの傾向はあれど、副反応の強さと抗体獲得に相関性は見受けられず｢副反応が強い=抗体が作られている、弱い=抗体が作られていない｣とは言えないようです。今後の研究次第ではわかりませんが参考までに。 20 Aug 2021 ReplyRetweetFavourite 39 followers raumfunkstelle @raumfunkstelle @BerndGnther15 @Karl_Lauterbach Mir ging’s auch gut, scheint mind. kurzfristig bzgl. Antikörpern (!) völlig egal zu sein (Pre): „Lack of post-vaccination symptoms following receipt of the BNT162b2 vaccine does not equate to lack of vaccine-induced antibodi 20 Aug 2021 ReplyRetweetFavourite 48 followers tune @keisuke4713 @kazuchancocone 「副反応が強いと免疫がつく」とデマをばらまいた奴らはどう思うでしょうね 米国でもワクチン関連症状重症度と抗体価に有意差なかったhttps://t.co/ml86ycCZFn 18 Aug 2021 ReplyRetweetFavourite 298 followers いっちー @a_songMI 原著論文↓ ただ査読前らしい https://t.co/2apXVibn1y 18 Aug 2021 ReplyRetweetFavourite 561 followers おたま @UG18353762 相関がないというデータあり(査読前)。 https://t.co/7Mmlojklvo 18 Aug 2021 ReplyRetweetFavourite 637 followers ９さん (Fully vaccinated with Moderna.) @930_jp https://t.co/CfGDOWp4WH 18 Aug 2021 ReplyRetweetFavourite 52 followers しれーの @Shirenbot https://t.co/LjvFAnf2Fi もとのプレプリント見ると若くて体重が軽いほど副反応が強い傾向が見えるなほんのちょっとだけ 18 Aug 2021 ReplyRetweetFavourite 557 followers 冨永良喜 @YujLFgyjRJ5SI29 @mamsan63 「副反応重症度と抗体価との相関はない」ようです。 https://t.co/kfPCzsTCNS 206 participants were evaluated. We found no correlation between vaccine-associated symptom severity scores and vaccine-induced antibody titers one month after vaccination. 17 Aug 2021 ReplyRetweetFavourite 43 followers satoshi @satoshi84570237 https://t.co/tocMAhKZez 17 Aug 2021 ReplyRetweetFavourite 2,673 followers UU @youx2youx2 @xzbuR98yyhjj そうとも言えなさそうかも？ https://t.co/nPDXkckFvH 16 Aug 2021 ReplyRetweetFavourite 76 followers Trev Scheffel @trevscheffel @ThatDudesMother @JamesLinnell1 @ClaudiaWest2019 @JustinTrudeau There is this false NIH claim stating that the spike protein through mRNA makes the body create antibodies https://t.co/8SGE8rnqBl Oh lord, CDC is way off base too https://t.co/7zJEnppWwZ h 15 Aug 2021 ReplyRetweetFavourite 16 followers ナッツ @xcoco_nutsx RT @BBT_Success: 「新コロワクチン副反応無双ですが、なにか？」的なプレプリント アメリカの医療従事者を対象として、ファイザーBNT162b2mRNAワクチン接種によって生じた副反応と、ワクチンによって誘発された抗体レベルの大きさとの関連性を明らかにした 1/… 13 Aug 2021 ReplyRetweetFavourite 930 followers 陣内 @JINNAI_ 体重とワクチン副反応が逆相関のソース、これかー 中央年齢高めだなあ https://t.co/6h0Cj5CaJJ 04 Aug 2021 ReplyRetweetFavourite 3,566 followers BBT_Success @BBT_Success @iwata910 新コロワク2回目接種時には、高確率で高重症度の副反応が発生する これで感染抑止や重症化抑止効果が期待できればいいのだが、現実は効果無（マイナス効果） 今般の新コロワク騒動は、『令和の脚気惨害』として歴史に残ることになりましたが、お体には十分ご留意下さい https://t.co/6ac2nnrYbC https://t.co/bxCQtZJU2n 03 Aug 2021 ReplyRetweetFavourite 697 followers Bob Brand @bobbrand_nl @DavidEerdmans De consensus lijkt te zijn: Nee, dat maakt geen verschil. Zie bijvoorbeeld deze recente studie: https://t.co/NV1jMtyrO1 https://t.co/P2lbeSU0LI 28 Jul 2021 ReplyRetweetFavourite 38 followers やま やま @uraramahiro2014 RT @BBT_Success: 「新コロワクチン副反応無双ですが、なにか？」的なプレプリント アメリカの医療従事者を対象として、ファイザーBNT162b2mRNAワクチン接種によって生じた副反応と、ワクチンによって誘発された抗体レベルの大きさとの関連性を明らかにした 1/… 25 Jul 2021 ReplyRetweetFavourite 220 followers 実験がんばれ @westail_seals RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 25 Jul 2021 ReplyRetweetFavourite 52 followers ִ @qualityflation RT @BBT_Success: また、 1.ワクチン接種後の症状は、年齢や体重と「逆相関」し『女性に多い』 ※新コロ重症者は、年齢や体重と「正相関」し『男性に多い』ことは非常に示唆的（BBT） 3/ https://t.co/TSg3jQXA2s https://t.… 24 Jul 2021 ReplyRetweetFavourite 174 followers Ptarmigan @Ptarmigan_TB RT @BBT_Success: 『年齢の高さ』は、性別、体重、人種とは関係なく、ワクチンによる【抗体価と負の関係】にあった ※若い人ほどワクチン接種後の抗体価が高くなり、副反応も大きくなるのは示唆的（BBT） 22/ https://t.co/TSg3jQXA2s ht… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: 若年者や女性に、ワクチン関連の副反応(AE) が多く発生するメカニズムは不明であるが ・【自然免疫機能の違い】によるものと考えられる 26/ https://t.co/TSg3jQXA2s 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: 女性は、男性に比べてワクチン1回目接種後の症状スコアが有意に高かった ※（平均8.0：IQR4-10）vs（平均5.7：IQR2-9）、p=0.006 18/ https://t.co/TSg3jQXA2s https://t.co/R1… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: また、「年齢が若い」こと、「性別が女性」であること、「体重が少ない」ことは、個別に評価した場合 ・『症状スコアが高い』ことと関連していた 16/ https://t.co/TSg3jQXA2s https://t.co/hzYlNAVcWk 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: この頻度は高重症度のグループでは約2倍となり、64％がワクチン2回目接種後に症状スコア10以上(高重症度)となった ※ワク1回目接種後に高重症度の症状があれば、『64％の確率』でワク2回目接種後に【高重症度】の副反応が発生する 12/ h… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: また、ワクチン1回目接種後に低重症度群の約35％が、ワクチン2回目接種後に症状スコアが10以上(高重症度)となった ※ワク1回目接種後に何らかの低症状があれば、『35％の確率』でワク2回目接種後に【高重症度】の副反応が発生する 11/ h… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: 全体として、ワクチン1回目接種の症状スコアとワクチン2回目接種の症状スコアには、正の相関が見られた ※rho=0.28,p<0.0001 10/ https://t.co/TSg3jQXA2s https://t.co/XEkP8B1tmH 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: ワクチン2回目接種後の『全身症状』の平均スコアは、ワクチン1回目接種後よりも有意に大きい ※（7.0：IQR 0-12）vs（3.1：IQR 0-5）,p<0.0001 9/ https://t.co/TSg3jQXA2s https:/… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: ワクチン2回目接種時に報告された症状スコアの平均値は、ワクチン1回目接種時よりも有意に大きい ※（10.62：IQR3-16）vs（7.3：IQR 3-10）,p<0.0001 8/ https://t.co/TSg3jQXA2s htt… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: CDCのVAERSでは、ワクチン2回目接種後に ・注射部位の痛み(79.3％) ・疲労(53.5％) ・筋肉痛(47.2％) ・頭痛(43.4％) ・悪寒(30.6％) ・発熱(29.2％) ・関節痛(23.5％) が【頻発】することが明ら… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: SARS-CoV-2 mRNAワクチンの特徴の1つは反応原性が高いことであり、第1-3相試験では ・『大多数』の患者に、局所および全身の反応が報告されている 6/ https://t.co/TSg3jQXA2s 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: 4.「年齢が高い」と抗体価が低い などが確認された 5/ https://t.co/TSg3jQXA2s https://t.co/EflWw1IQ9a 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: 3.ワクチン1回目接種後の症状スコアが高いと、ワクチン2回目接種後の症状スコアも高い 5/ https://t.co/TSg3jQXA2s https://t.co/fPh9tTVtGx 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: 2.『全身症状』は、2回目ワクチン接種後に多い 4/ https://t.co/TSg3jQXA2s https://t.co/Xi44mYv71f 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: また、 1.ワクチン接種後の症状は、年齢や体重と「逆相関」し『女性に多い』 ※新コロ重症者は、年齢や体重と「正相関」し『男性に多い』ことは非常に示唆的（BBT） 3/ https://t.co/TSg3jQXA2s https://t.… 24 Jul 2021 ReplyRetweetFavourite 1,286 followers DS元気HSP @okadaue_dsgenki RT @BBT_Success: 「新コロワクチン副反応無双ですが、なにか？」的なプレプリント アメリカの医療従事者を対象として、ファイザーBNT162b2mRNAワクチン接種によって生じた副反応と、ワクチンによって誘発された抗体レベルの大きさとの関連性を明らかにした 1/… 24 Jul 2021 ReplyRetweetFavourite 122 followers 角田知己 @Tomomo2001 RT @BBT_Success: そして現在 ・「感染抑止効果」がほぼ期待できない ・『重篤な副反応』付きの新コロワクチン接種 を強要されています 20/ https://t.co/eq6CAFPjA8 24 Jul 2021 ReplyRetweetFavourite 1,894 followers T.S @VurnunftS RT @BBT_Success: そして現在 ・「感染抑止効果」がほぼ期待できない ・『重篤な副反応』付きの新コロワクチン接種 を強要されています 20/ https://t.co/eq6CAFPjA8 24 Jul 2021 ReplyRetweetFavourite 40 followers 平庵 @33BOmq9yaupUY4r RT @BBT_Success: そして現在 ・「感染抑止効果」がほぼ期待できない ・『重篤な副反応』付きの新コロワクチン接種 を強要されています 20/ https://t.co/eq6CAFPjA8 24 Jul 2021 ReplyRetweetFavourite 3,566 followers BBT_Success @BBT_Success そして現在 ・「感染抑止効果」がほぼ期待できない ・『重篤な副反応』付きの新コロワクチン接種 を強要されています 20/ https://t.co/eq6CAFPjA8 24 Jul 2021 ReplyRetweetFavourite 624 followers むぎちゃ🥃ツイート自動生成【ついじぇね】作りました@個人開発 @MuggyTeaa RT @BBT_Success: 「新コロワクチン副反応無双ですが、なにか？」的なプレプリント アメリカの医療従事者を対象として、ファイザーBNT162b2mRNAワクチン接種によって生じた副反応と、ワクチンによって誘発された抗体レベルの大きさとの関連性を明らかにした 1/… 24 Jul 2021 ReplyRetweetFavourite 36 followers ねなしぐさ @Kyotonenasi RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 23 Jul 2021 ReplyRetweetFavourite 300 followers みなもと瑠華🐬小説ブル・エト鋭意執筆中💫アウトプット令和時代✨へGO💗 @lucamyg6 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… https://t.co/N1QicceaDy 23 Jul 2021 ReplyRetweetFavourite 277 followers オイカワヒロシ @oikawahiroshi RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 23 Jul 2021 ReplyRetweetFavourite 1,911 followers nimravus9 @nimravus61 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… https://t.co/N1QicceaDy 23 Jul 2021 ReplyRetweetFavourite 27 followers Ahu @ahu700 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… https://t.co/N1QicceaDy 23 Jul 2021 ReplyRetweetFavourite 13 followers しえろ @fIYKaJJoFrRHZGN RT @BBT_Success: 「新コロワクチン副反応無双ですが、なにか？」的なプレプリント アメリカの医療従事者を対象として、ファイザーBNT162b2mRNAワクチン接種によって生じた副反応と、ワクチンによって誘発された抗体レベルの大きさとの関連性を明らかにした 1/… 23 Jul 2021 ReplyRetweetFavourite 12 followers あゆか @RLZmwsDBSfTj8Nm RT @BBT_Success: また、 1.ワクチン接種後の症状は、年齢や体重と「逆相関」し『女性に多い』 ※新コロ重症者は、年齢や体重と「正相関」し『男性に多い』ことは非常に示唆的（BBT） 3/ https://t.co/TSg3jQXA2s https://t.… 23 Jul 2021 ReplyRetweetFavourite 2,764 followers 🇯🇵🇵🇼🇹🇼はたごや🇭🇰🇸🇬🇨🇭 @htgy_miltac572 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… https://t.co/N1QicceaDy 23 Jul 2021 ReplyRetweetFavourite 611 followers r-apricot 🇯🇵 🗣 #FreeSpeech @r_apricot RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… https://t.co/N1QicceaDy 23 Jul 2021 ReplyRetweetFavourite 566 followers ようこ🐯 @Yoyoyo05555 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 23 Jul 2021 ReplyRetweetFavourite 7,851 followers We Love TRUMP 🗣 🇺🇸 (Yuko) @shujamtaro RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 23 Jul 2021 ReplyRetweetFavourite 69 followers tom106 @tom10644324280 RT @BBT_Success: 「新コロワクチン副反応無双ですが、なにか？」的なプレプリント アメリカの医療従事者を対象として、ファイザーBNT162b2mRNAワクチン接種によって生じた副反応と、ワクチンによって誘発された抗体レベルの大きさとの関連性を明らかにした 1/… 23 Jul 2021 ReplyRetweetFavourite 71 followers ほいっちゃ @Hoichararin RT @alonechan: ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 23 Jul 2021 ReplyRetweetFavourite 85 followers 工藤 栄一 @o7CJreQ5vPQQwJO RT @alonechan: ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 23 Jul 2021 ReplyRetweetFavourite 299 followers るんりらら @haretaraiina_l RT @alonechan: ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 23 Jul 2021 ReplyRetweetFavourite 376 followers kaori @kaori_8739 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 23 Jul 2021 ReplyRetweetFavourite 15 followers masa.light @NBSLight RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 23 Jul 2021 ReplyRetweetFavourite 7 followers mikan @momookamomoo RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… https://t.co/N1QicceaDy 23 Jul 2021 ReplyRetweetFavourite 137 followers ジャック @hakugin_Jack RT @alonechan: ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 23 Jul 2021 ReplyRetweetFavourite 2,354 followers まさまさ @masasan04270 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 2,354 followers まさまさ @masasan04270 RT @BBT_Success: また、ワクチン1回目接種後に低重症度群の約35％が、ワクチン2回目接種後に症状スコアが10以上(高重症度)となった ※ワク1回目接種後に何らかの低症状があれば、『35％の確率』でワク2回目接種後に【高重症度】の副反応が発生する 11/ h… 22 Jul 2021 ReplyRetweetFavourite 2,354 followers まさまさ @masasan04270 RT @alonechan: ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 22 Jul 2021 ReplyRetweetFavourite 1,039 followers ぽこ🐾常識を捨てた自由人 @poko_www777 RT @alonechan: ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 https://t.co/b7oRmD1K8W 22 Jul 2021 ReplyRetweetFavourite 192 followers バビロン@未接種済み/コロ茶 @baloban_nabolab RT @BBT_Success: また、ワクチン1回目接種後に低重症度群の約35％が、ワクチン2回目接種後に症状スコアが10以上(高重症度)となった ※ワク1回目接種後に何らかの低症状があれば、『35％の確率』でワク2回目接種後に【高重症度】の副反応が発生する 11/ h… 22 Jul 2021 ReplyRetweetFavourite 1,535 followers ちゅうた @wankolove2020 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 517 followers Sarasvati(ｻﾗｽｳﾞｧﾃｨ) @sarasva42856167 RT @alonechan: ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 22 Jul 2021 ReplyRetweetFavourite 4,219 followers ひらめ🗣UBI❤️ @alonechan ワクチンのリスクが高い人 ●若い ●女性 ●軽体重 22 Jul 2021 ReplyRetweetFavourite 4,219 followers ひらめ🗣UBI❤️ @alonechan RT @BBT_Success: また、ワクチン1回目接種後に低重症度群の約35％が、ワクチン2回目接種後に症状スコアが10以上(高重症度)となった ※ワク1回目接種後に何らかの低症状があれば、『35％の確率』でワク2回目接種後に【高重症度】の副反応が発生する 11/ h… 22 Jul 2021 ReplyRetweetFavourite 15 followers 水のマモリビト @mz_mamoribito RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 https://t.co/sP3UCtNqUw 22 Jul 2021 ReplyRetweetFavourite 448 followers KMSAM.K @k_kmsam RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 47 followers とりあえずいろいろ @torimairoiro RT @BBT_Success: 2.『全身症状』は、2回目ワクチン接種後に多い 4/ https://t.co/TSg3jQXA2s https://t.co/Xi44mYv71f 22 Jul 2021 ReplyRetweetFavourite 42 followers taffy @taffy20020303 RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 22 Jul 2021 ReplyRetweetFavourite 81 followers ema0523💖🌎️🍀 @ema05231 RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 22 Jul 2021 ReplyRetweetFavourite 123 followers くーすけ @kusemonoarawaru RT @BBT_Success: また、 1.ワクチン接種後の症状は、年齢や体重と「逆相関」し『女性に多い』 ※新コロ重症者は、年齢や体重と「正相関」し『男性に多い』ことは非常に示唆的（BBT） 3/ https://t.co/TSg3jQXA2s https://t.… 22 Jul 2021 ReplyRetweetFavourite 24 followers 甚五郎8888 @8fukujin RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 https://t.co/sP3UCtNqUw 22 Jul 2021 ReplyRetweetFavourite 25 followers linus @linus87111002 RT @BBT_Success: 「新コロワクチン副反応無双ですが、なにか？」的なプレプリント アメリカの医療従事者を対象として、ファイザーBNT162b2mRNAワクチン接種によって生じた副反応と、ワクチンによって誘発された抗体レベルの大きさとの関連性を明らかにした 1/… 22 Jul 2021 ReplyRetweetFavourite 867 followers ほにゃにゃしか データを見ろ (こんな人たち) @_24_com RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 105 followers san 🗻💖💫 @san90345522 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 105 followers san 🗻💖💫 @san90345522 RT @BBT_Success: また、 1.ワクチン接種後の症状は、年齢や体重と「逆相関」し『女性に多い』 ※新コロ重症者は、年齢や体重と「正相関」し『男性に多い』ことは非常に示唆的（BBT） 3/ https://t.co/TSg3jQXA2s https://t.… 22 Jul 2021 ReplyRetweetFavourite 105 followers san 🗻💖💫 @san90345522 RT @BBT_Success: 2.『全身症状』は、2回目ワクチン接種後に多い 4/ https://t.co/TSg3jQXA2s https://t.co/Xi44mYv71f 22 Jul 2021 ReplyRetweetFavourite 105 followers san 🗻💖💫 @san90345522 RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 22 Jul 2021 ReplyRetweetFavourite 71 followers atsumin🌹🌎💫 @atsumin333 RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 22 Jul 2021 ReplyRetweetFavourite 44 followers Ikehi @Ikehiropons RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 849 followers 西園寺まりん @reomomonana RT @BBT_Success: 4.「年齢が高い」と抗体価が低い などが確認された 5/ https://t.co/TSg3jQXA2s https://t.co/EflWw1IQ9a 22 Jul 2021 ReplyRetweetFavourite 53 followers Alpherg-🇯🇵 💫 💖 @Alpherg7 RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 22 Jul 2021 ReplyRetweetFavourite 346 followers ma.k.o 日本人目覚めろ！ @ma_ko22859539 RT @BBT_Success: 4.「年齢が高い」と抗体価が低い などが確認された 5/ https://t.co/TSg3jQXA2s https://t.co/EflWw1IQ9a 22 Jul 2021 ReplyRetweetFavourite 346 followers ma.k.o 日本人目覚めろ！ @ma_ko22859539 RT @BBT_Success: 3.ワクチン1回目接種後の症状スコアが高いと、ワクチン2回目接種後の症状スコアも高い 5/ https://t.co/TSg3jQXA2s https://t.co/fPh9tTVtGx 22 Jul 2021 ReplyRetweetFavourite 346 followers ma.k.o 日本人目覚めろ！ @ma_ko22859539 RT @BBT_Success: 2.『全身症状』は、2回目ワクチン接種後に多い 4/ https://t.co/TSg3jQXA2s https://t.co/Xi44mYv71f 22 Jul 2021 ReplyRetweetFavourite 346 followers ma.k.o 日本人目覚めろ！ @ma_ko22859539 RT @BBT_Success: また、 1.ワクチン接種後の症状は、年齢や体重と「逆相関」し『女性に多い』 ※新コロ重症者は、年齢や体重と「正相関」し『男性に多い』ことは非常に示唆的（BBT） 3/ https://t.co/TSg3jQXA2s https://t.… 22 Jul 2021 ReplyRetweetFavourite 346 followers ma.k.o 日本人目覚めろ！ @ma_ko22859539 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 2,935 followers ヒーコ🐥日本人のコロナ生存率99.99% @PYIvb1PRGqdhgNY RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 23 followers めがね猫 @meganeneko3 RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 https://t.co/sP3UCtNqUw 22 Jul 2021 ReplyRetweetFavourite 932 followers みるくちぃ @shirochacha RT @MALight0010110: 若い女性ほど副反応ひどいってことね。 #ワクチン危険 22 Jul 2021 ReplyRetweetFavourite 31 followers 淳 @vbtFsYT0W0Zlxph RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 453 followers かつゆき（新垢） @katsuyuki_32 RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 216 followers 畑ペンギン @hatakepengin RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite 860 followers しおせんべい @6zpLwporigingsu RT @j_sato: 過去ないレベルの副反応のワクチンだと思うが、非リスク層ほど副反応が強いって、設計の根本に問題があると思うんだよね… 22 Jul 2021 ReplyRetweetFavourite Back to top PreviousNext Posted July 02, 2021. Download PDF Author Declarations Supplementary Material Data/Code XML Email Share Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers Si’Ana A. Coggins, Eric D. Laing, Cara H. Olsen, Emilie Goguet, Matthew Moser, Belinda M. Jackson-Thompson, Emily C. Samuels, Simon D. Pollett, David R. Tribble, Julian Davies, Luca Illinik, Monique Hollis-Perry, Santina E. Maiolatesi, Christopher A. Duplessis, Kathleen F. Ramsey, Anatalio E. Reyes, Yolanda Alcorta, Mimi A. Wong, Gregory Wang, Orlando Ortega, Edward Parmelee, Alyssa R. Lindrose, Andrew L. Snow, Allison M.W. Malloy, Andrew G. Letizia, John H. Powers III, Timothy H. Burgess, Christopher C. Broder, Edward Mitre medRxiv 2021.06.25.21259544; doi: https://doi.org/10.1101/2021.06.25.21259544 This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. Share This Article: Copy Citation Tools * * * COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv SUBJECT AREA * Infectious Diseases (except HIV/AIDS) Subject Areas All Articles * Addiction Medicine (108) * Allergy and Immunology (298) * Anesthesia (72) * Cardiovascular Medicine (656) * Dentistry and Oral Medicine (119) * Dermatology (77) * Emergency Medicine (212) * Endocrinology (including Diabetes Mellitus and Metabolic Disease) (296) * Epidemiology (7182) * Forensic Medicine (4) * Gastroenterology (298) * Genetic and Genomic Medicine (1269) * Geriatric Medicine (124) * Health Economics (304) * Health Informatics (996) * Health Policy (519) * Health Systems and Quality Improvement (350) * Hematology (150) * HIV/AIDS (279) * Infectious Diseases (except HIV/AIDS) (8427) * Intensive Care and Critical Care Medicine (478) * Medical Education (159) * Medical Ethics (38) * Nephrology (149) * Neurology (1213) * Nursing (63) * Nutrition (195) * Obstetrics and Gynecology (253) * Occupational and Environmental Health (360) * Oncology (689) * Ophthalmology (213) * Orthopedics (67) * Otolaryngology (135) * Pain Medicine (72) * Palliative Medicine (30) * Pathology (195) * Pediatrics (406) * Pharmacology and Therapeutics (194) * Primary Care Research (157) * Psychiatry and Clinical Psychology (1346) * Public and Global Health (3015) * Radiology and Imaging (494) * Rehabilitation Medicine and Physical Therapy (241) * Respiratory Medicine (412) * Rheumatology (157) * Sexual and Reproductive Health (115) * Sports Medicine (113) * Surgery (149) * Toxicology (31) * Transplantation (66) * Urology (49) Email this Articleclose Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Citation Toolsclose Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers Si’Ana A. Coggins, Eric D. Laing, Cara H. Olsen, Emilie Goguet, Matthew Moser, Belinda M. Jackson-Thompson, Emily C. Samuels, Simon D. Pollett, David R. Tribble, Julian Davies, Luca Illinik, Monique Hollis-Perry, Santina E. Maiolatesi, Christopher A. Duplessis, Kathleen F. Ramsey, Anatalio E. Reyes, Yolanda Alcorta, Mimi A. Wong, Gregory Wang, Orlando Ortega, Edward Parmelee, Alyssa R. Lindrose, Andrew L. Snow, Allison M.W. Malloy, Andrew G. Letizia, John H. Powers III, Timothy H. Burgess, Christopher C. Broder, Edward Mitre medRxiv 2021.06.25.21259544; doi: https://doi.org/10.1101/2021.06.25.21259544 This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. CITATION MANAGER FORMATS * BibTeX * Bookends * EasyBib * EndNote (tagged) * EndNote 8 (xml) * Medlars * Mendeley * Papers * RefWorks Tagged * Ref Manager * RIS * Zotero We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more